Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 24;25(19):10239.
doi: 10.3390/ijms251910239.

The Effects of Brodalumab on the Fungal Microbiome in Patients with Psoriasis

Admir Vižlin  1 , Ajša Bajramović  2 , Ylva Andersch Björkman  1   3 , Yadhu Kumar  4 , Maria Göthe  4 , Martin Gillstedt  1   3 , Amra Osmančević  1   3
Affiliations

The Effects of Brodalumab on the Fungal Microbiome in Patients with Psoriasis

Admir Vižlin et al. Int J Mol Sci. .

Abstract

The gut microbiota plays a critical role in immune system function, with dysbiosis linked to systemic inflammation, contributing to conditions like psoriasis and depression. Although biological treatments for severe psoriasis are known to impact gut bacteria, less is understood about their effects on fungi. This study aims to investigate fungal gut microbiota changes in psoriasis patients transitioning from TNF-α inhibitors to brodalumab. Fecal samples from 20 patients were analyzed using Illumina MiSeq sequencing of the ITS2 region of 18S rRNA. Microbial diversity was assessed through Bray-Curtis dissimilarity and the Shannon-Wiener index. Clinical outcomes were measured using clinical scores for psoriasis and depression severity, with statistical analysis performed via Wilcoxon signed-rank tests and PERMANOVA. Results showed that Ascomycota was the dominant fungal phylum in both treatment groups, with Saccharomyces, Penicillium, Candida, and Debaryomyces as prevalent genera. No significant changes occurred at the phylum level after switching to brodalumab, though minor genome-level variations were observed. Beta diversity analysis highlighted inter-patient variability, with no significant correlation between fungal composition and clinical outcomes. Despite improved clinical scores, the fungal gut microbiota remained largely stable, suggesting that brodalumab does not significantly alter fungal communities in psoriasis patients. Further research is needed for a comprehensive understanding.

Keywords: TNF-alpha inhibitors; brodalumab; fungi; gut microbiome; psoriasis.

PubMed Disclaimer

Conflict of interest statement

Amra Osmančević has participated or held lectures in AB for AbbVie, Celgene/Amgen, Eli Lilly, Novartis, Pfizer, Meda, UCB-Pharma, Janssen Cilag, Allmiral, Kyowa Kirin, Sanofi, Bristol-Myers Squbb, Recordati Rare Diseases, and Leo Pharma and conducted clinical trials for Novartis, Abbvie, Leo Pharma, Celgene, Janssen Cilag, UCB-Pharma, and Boehringer Ingelheim. Authors Yadhu Kumar and Maria Göthe were employed by the company Eurofins Genomics. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The bar chart presents the composition of the gut microbiota on the phylum level before (TNF) and after (B) the switch to brodalumab. Each number represents one patient (p(n)). Each bar is a sample. The y-axis represents the relative abundance of phyla given as OTU composition. Five subjects did not submit samples after the switch, thus excluding them from the comparative analysis (total of 14 patients remained in the final analysis).
Figure 2
Figure 2
The bar chart presents the composition of the gut microbiota on the genus level before (TNF) and after (B) the switch to brodalumab. Each number represents one patient (p(n)). Each bar is a sample. The y-axis represents the relative abundance of phyla given as OTU composition.
Figure 3
Figure 3
PCoA at the genus (a) and phylum (b) level. Patients are represented as specific colors, while the condition before the switch (TNF) is represented as a triangle and the condition after the switch (B) is represented as a circle. The distances between points (shapes) reflect the dissimilarity between microbial communities.
Figure 4
Figure 4
Heat map of the beta diversity of fungi phyla. Red represents a value of 1, high dissimilarity between samples; blue represents a value of 0, low dissimilarity between samples.
Figure 5
Figure 5
Violin plot showing the distributions of the Shannon–Wiener diversity indices across treatment groups. The pink violin represents diversity indices from patients before treatment (TNF), while the green violin represents diversity indices after treatment (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Pérez J.C. Fungi of the human gut microbiota: Roles and significance. Int. J. Med. Microbiol. 2021;311:151490. doi: 10.1016/j.ijmm.2021.151490. - DOI - PubMed
    1. Nash A.K., Auchtung T.A., Wong M.C., Smith D.P., Gesell J.R., Ross M.C., Stewart C.J., Metcalf G.A., Muzny D.M., Gibbs R.A., et al. The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome. 2017;5:153. doi: 10.1186/s40168-017-0373-4. - DOI - PMC - PubMed
    1. Gaitanis G., Velegraki A., Mayser P., Bassukas I.D. Skin diseases associated with Malassezia yeasts: Facts and controversies. Clin. Dermatol. 2013;31:455–463. doi: 10.1016/j.clindermatol.2013.01.012. - DOI - PubMed
    1. Richard M.L., Lamas B., Liguori G., Hoffmann T.W., Sokol H. Gut Fungal Microbiota. Inflamm. Bowel Dis. 2015;21:656–665. doi: 10.1097/MIB.0000000000000261. - DOI - PubMed
    1. Jiang H.Y., Pan L.Y., Zhang X., Zhang Z., Zhou Y.Y., Ruan B. Altered gut bacterial–fungal interkingdom networks in patients with current depressive episode. Brain Behav. 2020;10:e01677. doi: 10.1002/brb3.1677. - DOI - PMC - PubMed

Substances

LinkOut - more resources